Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 15/20 | 0.49 |
| ▸ | RAB9A | P51151 | 15/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.47 |
| ▸ | TP53 | P04637 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5873017 | 0.82 | MAPT (0.47) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL5872850 | 0.80 | MAP2K1 (0.56) | SMN1; SMN2MAPK1KMT2AMEN1TDP1 | |
| SCHEMBL5873050 | 0.80 | AURKA (0.45) | ALDH1A1KMT2AMEN1TDP1 | |
| SCHEMBL5872858 | 0.79 | MAP2K1 (0.51) | SMN1; SMN2MAPK1KMT2AMEN1TDP1 | |
| SCHEMBL5872778 | 0.79 | KCNQ3 (0.46) | KMT2AMEN1TDP1 | |
| SCHEMBL5873019 | 0.79 | MAPT (0.47) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL5872912 | 0.78 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL5873057 | 0.78 | SORT1 (0.47) | NPC1TP53ALDH1A1HTTKMT2A | |
| SCHEMBL24849049 | 0.78 | MAP2K1 (0.56) | SMN1; SMN2MAPK1KMT2AMEN1TDP1 | |
| SCHEMBL4853895 | 0.77 | MEN1 (0.62) | MAPK1KMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001905-B2 | Substituted diarylamines as MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | BIWERSI CATHLIN (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | NRAS, MAPK6, MAPK12 | NPC1 1169/4885RAB9A 3021/4885SMN1; SMN2 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.